A phase I trial of azacitidine and nanoparticle albumin bound paclitaxel in patients with advanced or metastatic solid tumors

作者：Adam L. Cohen, Abhijit Ray, Matthew Van Brocklin, David Burnett, Randy C. Bowen, Donna Lynn Dyess, Thomas W. Butler, Theresa Dumlao, Hung T. Khong · 发表于：Oncotarget · 年份：2016 · DOI：10.18632/oncotarget.14183 · 被引用次数：27 · 研究领域：Bone and Dental Protein Studies、Nanoparticle-Based Drug Delivery、Epigenetics and DNA Methylation

// Adam L. Cohen 1, * , Abhijit Ray 2, * , Matthew Van Brocklin 3 , David M. Burnett 3 , Randy C. Bowen 4 , Donna L. Dyess 5 , Thomas W. Butler 5 , Theresa Dumlao 6 and Hung T. Khong 1 1 Department of Medicine, Division of Oncology, University of Utah, Huntsman Cancer Institute, Salt Lake City, UT, USA 2 Division of Oncology, University of Utah, Huntsman Cancer Institute, Salt Lake City, UT, USA 3 Department of Surgery, University of Utah, Huntsman Cancer Institute, Salt Lake City, UT, USA 4 Department of Medicine, University of Utah, Salt Lake City, UT, USA 5 University of South Alabama, Mitchell Cancer Institute, Mobile, AL, USA 6 Banner MD Anderson Cancer Center, Gilbert, AZ, USA * These authors have contributed equally to this work Correspondence to: Hung T. Khong, email: hung.khong@hci.utah.edu Keywords: nab-paclitaxel, azacitidine, solid tumor, phase I clinical trials, SPARC Received: August 19, 2016     Accepted: November 18, 2016     Published: December 26, 2016 ABSTRACT Background: Secreted protein acidic and rich in cysteine (SPARC), an albumin-binding protein, is downregulated by hypermethylation in many cancers. Hypomethylating agents such as azacitidine can upregulate SPARC in tumors, which may enhance the accumulation of albumin-bound drugs at tumor site. The objectives of this phase I trial was to determine the safety and maximum tolerated dose and to assess any clinical activity of the combination of azacytidine and week...